- ZMapp, developed by Mapp Biopharmaceutical, was used in August to treat several patients in the ongoing Ebola virus outbreak
- Five of the seven patients who received ZMapp survived
- Now knowing how ZMapp targets Ebola, scientists can compare all newly discovered anti-Ebola antibodies and formulate a better immunotherapeutic drug